somatostatin ,

Somatostatin 1-28 acetate circulates in human plasma. Approximately 46% of the total somatostatin-like immunoreactivity in plasma is due to Somatostatin 1-28 acetate.

[Tyr1]-Somatostatin-14 may bind to SSTR2.

[Tyr11]-Somatostatin is a neuroactive peptide utilized in proteomics research. It belongs to a class of neuroactive substances that play a role in modulating retinal physiology.

[Tyr12] Somatostatin 28 (1-14) is an analogue of the N-terminal fragment of the neuropeptide Somatostatin-28, encompassing the first 14 amino acids of the sequence.

[Nle8] Somatostatin (1-28), a derivative of somatostatin (1-28) with norleucine (Nle) substituting for methionine at position 8, enhances amylase release and elevates cyclic AMP levels in pancreatic acini [1].

'(D-Phe5,Cys6,11,N-Me-D-Trp8)-Somatostatin-14 (5-12) amide (Compound 4) is a somatostatin analogue exhibiting varying affinity for somatostatin receptors, with dissociation constants (Kd) of 0.61 nM for SSTR5, 11.05 nM for SSTR3, 23.5 nM for SSTR2, 1200 nM for SSTR1, and >1000 nM for SSTR4, respectively [1].'

Tyr-(D-Dab4,Arg5,D-Trp8)-cyclo-Somatostatin-14 (4-11) is a somatostatin agonist used in cancer research [1].

[D-Trp8] Somatostatin-14 is a potent tetradecapeptide analog of native somatostatin, exhibiting increased efficacy [1].

[D-Trp8,Tyr11] Somatostatin, an analogue of the hormone somatostatin that modulates numerous bodily functions, is characterized by the substitution of DTrp8, which can enhance its stability [1].

(D-Trp8,D-Cys14)-Somatostatin-14, a synthetic analogue of somatostatin, is used in the research of metabolic-related diseases [1] [2].

Somatostatin acetate is an endogenously secreted inhibitor of cell proliferation with potential antitumor activity for the study of cancer and neurological disorders.

Somatostatin-28 (1-14) is an N-terminal fragment of the neuropeptide somatostatin-28, which originates from the posttranslational cleavage of prosomatostatin, derived from the larger precursor preprosomatostatin.

[Nle8] Somatostatin (1-28) TFA is a derivative of somatostatin (1-28) where methionine at position 8 is replaced with norleucine. This compound enhances the release of amylase and increases cyclic AMP in pancreatic acini.

Tyr-Somatostatin-14 acetate is a customized peptide that adds a Tyrosine amino acid to Somatostatin-14.

Tyr-Somatostatin-28 is a somatostatin derivative comprising Somatostatin-28 with an additional Tyrosine amino acid [1].

Somatostatin-28 (1-12) is a fragment of somatostatin that is monitored in brain tissue to track the processing of somatostatin.

Tyr-Somatostatin-14 is a modified peptide incorporating an additional Tyrosine (amino acid) into the structure of Somatostatin-14.

Somatostatin is an endogenous neuropeptide hormone found in the brain and pancreas. Somatostatin binds several isoforms of the somatostatin receptor, exhibiting anxiolytic, antiepileptic/anticonvulsant, and anorexigenic activities.

Somatostatin receptor agonist, derived from the post-translational cleavage of prosomatostatin.

Somatostatin-14 (reduced) (SST 14) is a peptide identified through polypeptide screening, which is a research tool primarily utilizing immunoassay techniques to isolate active polypeptides. This method is applicable in protein interactions, functional analysis, antigen epitope screening, and is particularly relevant in the study and development of active molecules.

L-797,591 hydrochloride is active for somatostatin receptor isoform 1 (SSTR1). L-797,591 hydrochloride is commonly used in combination with AG1478 to enhance p-ERK5 expression in SSTR1 cells. L-797,591 hydrochloride significantly enhanced p38 phosphorylation in cotransfected cells, and this effect was reversed in combination with AG1478.

AGI-43192 is a potent methionine adenosine transferase 2A (MAT2A) inhibitor that penetrates the blood-brain barrier. AGI-43192 inhibits S-adenosine methionine (SAM) production metabolic enzyme and methionine adenosine transferase 2A (MAT2A), which has the potential to study the role of SAM regulation in the central nervous system (CNS) and the treatment of cancer diseases.

AGI-41998 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A) that penetrates the blood-brain barrier. It inhibits S-adenosylmethionine (SAM) metabolizing enzymes and MAT2A for the treatment of cancer and for studying the role of SAM regulation in the central nervous system (CNS).

2-Aminoethanethiol (Cysteamine) is a Cystine Depleting Agent. The mechanism of action of cysteamine is as a Cystine Disulfide Reduction.